CASI PHARMACEUTICALS INC.
🇰🇾Cayman Islands
- Country
- 🇰🇾Cayman Islands
- Ownership
- Public
- Employees
- 243
- Market Cap
- $100.6M
Safety and Efficacy Study of rhAngiostatin Administered in Combination With Paclitaxel and Carboplatin to Patients With Non-Small-Cell Lung Cancer
Phase 2
Completed
- Conditions
- First Posted Date
- 2002-11-15
- Last Posted Date
- 2009-01-09
- Lead Sponsor
- CASI Pharmaceuticals, Inc.
- Registration Number
- NCT00049790
- Locations
- 🇺🇸
Indiana Cancer Pavilion, Indiana University, Indianapolis, Indiana, United States
© Copyright 2024. All Rights Reserved by MedPath